Gulf Pharma Industries Julphar announces Strategy 2030

Gulf Pharma Industries Julphar begins its Strategy 2030 to enable transformational growth with six pillars, covering new products & geographical expansion

Gulf Pharmaceutical Industries Julphar has announced its Strategy 2030 which will involve sustainable growth and transformation designed to create vastly enhanced value for its stakeholders. 

Founded in 2019 and based in Ras Al Khaimah, UAE, Julphar serves patients in the Middle East and Africa by manufacturing general medicines, branded ones, and APIs (active pharmaceutical ingredients) to cover a range of health problems. The company has 13 facilities which produce over half a million boxes of medicine each day, from vaccines to tablets, syrups to creams.

Julphar set to become the leading pharmaceutical company in MENA

Strategy 2030 will expand Julphar’s revenue with six central growth pillars:

  • Maximising revenue from current product portfolio
  • New product launches
  • Geographical expansions
  • Strategic business initiatives
  • Advanced specialty products initiative
  • In-organic growth initiatives

With Strategy 2030, Julphar hopes that this growth strategy will move it to be the leading pharmaceutical company in the MENA region - and beyond. Julphar is also increasing its vaccine production and biotechnology capabilities with new technologies.

 

Entering a defining moment in Julphar’s transformational journey with its innovative healthcare solutions

“Setting out our Strategy 2030 today, we are committed to concentrating our efforts and resources on our priority growth platforms and pipeline projects,” said Dr. Essam Mohamed, Chief Executive Officer of Julphar. “Despite the enormous challenges and the global pandemic, Julphar achieved one of the most successful strategic turnaround stories; we have reached our objectives and greatly exceeded expectations, and now we are entering a defining moment in our transformational journey.

“We are confident that we are well-positioned for a bright future by delivering new, innovative healthcare solutions into the hands of our patients. To release Julphar’s full potential, we must now increase profitability and make bold investments in the best and most innovative areas of treatment for the patients and communities we serve.”

Julphar's modern manufacturing facilities in Ras Al Khaimah make the company an ideal pharma partner of choice and the company has already signed manufacturing contracts with over ten leading companies for technology transfer and packaging.

Share

Featured Articles

Philip Morris International (PMI) in agreement with KT&G

PMI and KT&G are building a smoke-free world. In a new agreement between the two companies, smoke-free alternatives are within reach for smokers

Health tech leader Philips shares sustainability ambition

Roy Jakobs, Royal Philips CEO, says the health technology company’s sustainability impact plan will ‘enhance accountability & strengthen talent’

Automating gene therapy & pharma discovery at Automata

Sonia Jassi, Drug Discovery & Synthetic Biology Lead at Automata, explains how automation increases efficiency in gene therapy laboratories

Itai Hayut, CEO of Scopio Labs, on AI & blood cancer

Technology & AI

2023 predictions with Harshit Jain, global CEO of Doceree

Telehealth & COVID-19

Wolters Kluwer Health: health equity and telehealth

Telehealth & COVID-19